Vestal Point Capital LP Purchases Shares of 525,000 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Vestal Point Capital LP purchased a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 525,000 shares of the company's stock, valued at approximately $3,644,000. Vestal Point Capital LP owned 1.00% of Zevra Therapeutics at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ZVRA. International Assets Investment Management LLC boosted its stake in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after acquiring an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Zevra Therapeutics during the first quarter worth approximately $64,000. Hunter Associates Investment Management LLC acquired a new stake in Zevra Therapeutics in the third quarter valued at approximately $92,000. Intech Investment Management LLC purchased a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $95,000. Finally, SG Americas Securities LLC acquired a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $105,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Price Performance

Shares of ZVRA stock traded down $0.17 during trading hours on Friday, reaching $9.33. The company had a trading volume of 231,055 shares, compared to its average volume of 548,185. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The company has a market capitalization of $498.04 million, a price-to-earnings ratio of -4.82 and a beta of 1.93. The stock has a fifty day moving average of $8.33 and a 200-day moving average of $6.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts' expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter in the previous year, the company earned ($0.40) earnings per share. On average, equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ZVRA shares. Maxim Group boosted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, September 24th. Cantor Fitzgerald reissued an "overweight" rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. JMP Securities began coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 price target on the stock. Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and an average price target of $21.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.